Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Ultrasound-Guided Optimization of Preoperative Chemoradiotherapy Using ¹³¹I SPECT/CT for Enhanced Targeting in Differentiated Thyroid Carcinoma.","authors":"Baogang Shi, Xiaobo Xu, Xiaofeng Xia, Quanyong Wang","doi":"10.1177/10849785251376447","DOIUrl":"https://doi.org/10.1177/10849785251376447","url":null,"abstract":"<p><p>To properly target tumors during preoperative chemoradiotherapy, differentiated thyroid carcinoma (DTC) must be careful. This method increases treatment success and decreases recurrence. Ultrasound coupled with SPECT/CT may provide novel localization and dose planning possibilities. Many systems solely use anatomical or functional imaging. This may result in insufficient dosage delivery and wasted radiation exposure to healthy tissues. These issues are addressed by Dual-Modality Imaging-Guided Adaptive Chemoradiotherapy Planning (DMI-ACP). This innovative approach combines real-time ultrasound imaging with 6 Å SPECT/CT imaging for precise tumor delineation and tailored dosimetry. This system enables clinicians to adjust chemoradiotherapy regimens by seamlessly integrating functional iodine absorption data with anatomical characteristics, thereby targeting therapy to cancerous areas. The outcomes of this method for patients with DTC were promising, including better lesion targeting, reduced radiation exposure to healthy tissues, and improved chemotherapeutic dose distribution. In clinical evaluations, the DMI-ACP framework demonstrated a sensitivity of 94% and a specificity of 89% in identifying malignant lesions compared with traditional imaging techniques. Furthermore, the integration of adaptive planning resulted in a 20% improvement in tumor control probability and a 15% reduction in exposure to surrounding healthy tissue, as assessed through dosimetric analysis. 2023075 Nanjing Drum Tower Hospital Group Suqian Hospital/The Affiliated Suqian Hospital of Xuzhou Medical University.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Severity Detection in Histopathological Ovarian Cancer: Rank-Based Leaf Wind Optimization and Alpha Piecewise Linear Fuzzy Techniques.","authors":"Venkata Lakshmi S, Chandaka Pavan Sathish, Uma Pyla, Sravani K, Jayasree Pinajala, Nitalaksheswara Rao Kolukula, James Stephen Meka","doi":"10.1177/10849785251380023","DOIUrl":"https://doi.org/10.1177/10849785251380023","url":null,"abstract":"<p><p><b><i>Background:</i></b> Ovarian cancer (OC) often goes undetected until advanced stages due to mild early symptoms. <b><i>Methods:</i></b> This research proposes a novel methodology for assessing OC severity through histopathological image analysis, utilizing Rank-Based Leaf in Wind Optimization and Alpha Piecewise Linear Fuzzy techniques. It enhances tissue image quality through normalization and Contrast Limited Adaptive Histogram Equalization, employs ResNet 50 with Inception v4 for feature extraction, and uses a ranking layer to prioritize key features. <b><i>Results:</i></b> The model achieved 99.25% accuracy and 97.98% precision, effectively classifying tumor severity levels under diagnostic uncertainty. <b><i>Conclusion:</i></b> This robust approach enhances diagnostic accuracy, supports early detection, and improves treatment planning. Future work will explore cross-validation, model pruning, and real-time integration for clinical applications.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPINK4 Expression as a Predictive Biomarker for Radiolabeled Immune Modulator Therapy in Advanced Colorectal Cancer.","authors":"Haihua Long, Yongqi Shen, Shuting Li, Hongxiang Kong, Jianqin Liang","doi":"10.1177/10849785251379696","DOIUrl":"https://doi.org/10.1177/10849785251379696","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains a significant factor contributing to the morbidity and mortality rates linked with cancer throughout the world, especially in its stages of progression. Increasingly attractive therapeutic options include immune modulation combined with preoperative chemotherapy and radiation therapy (CRT). Recent studies have revealed that the protein serine peptidase inhibitor Kazal type 4 (SPINK4), which is abundantly expressed in gastrointestinal tract tissues, plays a role in immune evasion and treatment resistance in cancers. This meta-analysis aims to assess the relationship between SPINK4 expression levels and the therapeutic effectiveness of radiolabeled immune modulators in patients with advanced CRC who are undergoing preoperative chemotherapy and radiation treatment. The degree of SPINK4 expression and a lower objective response to radiolabeled immune modulators showed a statistically significant link. Conversely, patients with low SPINK4 expression have more favorable treatment responses and ongoing clinical improvement following CRT. High SpINK4 expression can act as a negative prognostic biomarker for radiolabeled immune control in advanced CRC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Cancer Therapies on Immunoglobulin Synthesis: A Review of Mechanisms, Clinical Implications, and Mitigation Strategies.","authors":"Rahaman Shaik, Huda Khan, Mohammed Ziya Salomi, Fatima Uz Zehra, Srujan Kumar Vempati, Mohammed Riyaz, Shaik Azeeza","doi":"10.1177/10849785251384813","DOIUrl":"https://doi.org/10.1177/10849785251384813","url":null,"abstract":"<p><p>Chemotherapy, radiation, and targeted biological treatments are examples of cancer therapies that have a significant effect on the immune system. They frequently interfere with the manufacture of immunoglobulins (Igs), which results in immunodeficiency. The processes via which these medications affect B cell activity and antibody production are examined in this review, with an emphasis on cytokine regulation, bone marrow suppression, and therapy-induced lymphopenia. Reduced Ig levels can have clinical repercussions such as increased vulnerability to infections, decreased effectiveness of vaccinations, and compromised immune monitoring. This study also looks at new and existing methods to lessen these consequences, including immunomodulatory techniques, prophylactic antibiotics, and Ig replacement treatment. Optimizing patient outcomes, striking a balance between immunological protection and oncologic efficacy, and directing future research in supportive cancer care all depend on an understanding of how humoral immunity and cancer treatment interact.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-Parallel Artificial Intelligence Framework for Breast Cancer Grading via High-Intensity Ultrasound and Biomarkers.","authors":"Pritee Parwekar, Krishna Kant Agrawal, Jabir Ali, Shilpa Gundagatti, Dharmveer Singh Rajpoot, Tanveer Ahmed, Ankit Vidyarthi","doi":"10.1177/10849785251383328","DOIUrl":"https://doi.org/10.1177/10849785251383328","url":null,"abstract":"<p><p><b><i>Background:</i></b> Accurate and noninvasive breast cancer grading and therapy monitoring remain critical challenges in oncology. Traditional methods often rely on invasive histopathological assessments or imaging-only techniques, which may not fully capture the molecular and morphological intricacies of tumor response. <b><i>Method:</i></b> This article presents a novel, noninvasive framework for breast cancer analysis and therapy monitoring that combines two parallel mechanisms: (1) a dual-stream convolutional neural network (CNN) processing high-intensity ultrasound images, and (2) a biomarker-aware CNN stream utilizing patient-specific breast cancer biomarkers, including carbohydrate antigen 15-3, carcinoembryonic antigen, and human epidermal growth factor receptor 2 levels. The imaging stream extracts spatial and morphological features, while the biomarker stream encodes quantitative molecular indicators, enabling a multimodal understanding of tumor characteristics. The outputs from both streams are fused to predict the cancer grade (G1-G3) with high reliability. <b><i>Results:</i></b> Experimental evaluation on a cohort of pre- and postchemotherapy patients demonstrated the effectiveness of the proposed approach, achieving an overall grading accuracy of 97.8%, with an area under the curve of 0.981 for malignancy classification. The model also enables quantitative post-therapy analysis, revealing an average tumor response improvement of 41.3% across the test set, as measured by predicted regression in grade and changes in biomarker-imaging correlation. <b><i>Conclusions:</i></b> This dual-parallel artificial intelligence strategy offers a promising noninvasive alternative to traditional histopathological and imaging-alone methods, supporting real-time cancer monitoring and personalized treatment evaluation. The integration of high-resolution imaging with biomolecular data significantly enhances diagnostic depth, paving the way for intelligent, patient-specific breast cancer management.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ELAVL1-Regulated Bone Morphogenetic Protein 2 as a Predictive Biomarker for Ultrasound Therapy Response in Oral Squamous Cell Carcinoma Bone Infiltration.","authors":"Jing Feng, Feng Jiang, Jin Fang","doi":"10.1177/10849785251382695","DOIUrl":"https://doi.org/10.1177/10849785251382695","url":null,"abstract":"<p><p><b><i>Background:</i></b> Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the neck and head region. A major contributor to poor prognosis in OSCC is bone infiltration. Bone morphogenetic protein 2 (BMP2), known to promote tumor progression and bone metastasis in several cancers, has recently emerged as a potential molecular mediator of OSCC invasiveness. However, its role in predicting therapeutic response-particularly in emerging modalities like ultrasound-based therapies-remains unexplored. <b><i>Methods:</i></b> The authors assessed BMP2 expression in OSCC tissues and cell lines using RT-qPCR. Functional assays were conducted to evaluate malignant cellular behaviors, including proliferation and epithelial-mesenchymal transition (EMT). Osteoclast differentiation and bone resorption were quantified via TRAP staining and resorption pit assays. RNA-binding interactions were identified using RNA immunoprecipitation and biotin pull-down assays. <b><i>Results:</i></b> BMP2 was significantly overexpressed in OSCC and strongly correlated with bone infiltration. Its upregulation enhanced OSCC cell proliferation, EMT, and osteoclast-mediated bone resorption. <i>In vivo</i>, BMP2 knockdown suppressed tumor growth and bone invasion. Mechanistically, the authors identified ELAVL1 as a key RNA-binding protein that stabilized BMP2 transcripts, thereby promoting its expression. Moreover, BMP2 overexpression rescued the tumor-suppressive effects of ELAVL1 silencing, highlighting a critical regulatory axis. Given the role of BMP2 in modulating the tumor microenvironment and its association with bone-invasive phenotypes, it holds potential as a predictive biomarker for response to ultrasound-enhanced therapeutic strategies. <b><i>Conclusions:</i></b> ELAVL1-regulated BMP2 promotes OSCC progression and bone infiltration and may serve as a valuable predictive biomarker for therapeutic response in ultrasound-guided biotherapies.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of CD44 in Colorectal Cancer: Molecular Mechanisms, Isoform Interactions, and Targeted Treatments to Address Tumorigenesis and Chemoresistance.","authors":"Megha Jha, Sankha Bhattacharya, Girdhari Lal Gupta, Bhupendra Prajapati, Devesh U Kapoor","doi":"10.1177/10849785251381993","DOIUrl":"https://doi.org/10.1177/10849785251381993","url":null,"abstract":"<p><p>Cluster of differentiation 44 (CD44), a versatile transmembrane glycoprotein, plays a crucial role in the progression, metastasis, and therapeutic resistance of colorectal cancer (CRC). This review clarifies CD44's essential function in CRC via connections with the extracellular matrix (ECM), particularly hyaluronic acid (HA), and important signaling pathways, such as Ras/mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt). The overexpression of CD44, especially its variant isoforms (CD44v), is associated with aggressive tumor characteristics, increased cancer stem cell (CSC) traits, and unfavorable outcomes in CRC patients. CD44 enhances tumor cell attachment, movement, infiltration, and epithelial-mesenchymal transition, facilitating metastasis and resistance to chemotherapy. Its interactions with ECM elements and receptors, such as the epidermal growth factor receptor, enhance tumor growth and survival signaling. Therapeutic approaches aimed at CD44, such as monoclonal antibodies, small interfering RNAs, and nanoparticles targeting CD44 (e.g., CSA-SS-CXB@CPT, A@HAP), show encouraging antitumor effectiveness by interrupting CD44-HA interactions and the subsequent signaling pathways. Preclinical studies emphasize the benefits of pairing anti-CD44 therapies with PI3K/Akt or Wnt/β-catenin inhibitors to improve results. This review combines CD44's molecular mechanisms, isoform-specific functions, and CSC regulation in CRC, highlighting the potential as a biomarker and therapeutic target to enhance patient outcomes.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Anesthetic Technique on the Postoperative Biological Stress Response in Thyroid Cancer Patients Receiving Psychological Intervention During Ultrasound-Guided Thyroidectomy.","authors":"Yunyao Deng, Mei Peng, Kun Zhou","doi":"10.1177/10849785251380029","DOIUrl":"https://doi.org/10.1177/10849785251380029","url":null,"abstract":"<p><p><b><i>Objective:</i></b> To examine the influence of various anesthetic techniques on the postoperative biological stress response in thyroid cancer (TC) patients receiving psychological nursing intervention during ultrasound-guided radical thyroidectomy. <b><i>Methods:</i></b> TC patients undergoing ultrasound-guided radical thyroidectomy at The Third Affiliated Hospital of Southern Medical University between January 2020 and June 2022 were enrolled and randomly assigned to two groups based on anesthetic protocol. Both groups received general anesthesia and standardized psychological nursing intervention. Intervention group received remifentanil-propofol anesthesia, whereas reference group received sevoflurane-propofol anesthesia. Hemodynamic parameters, serum stress biomarkers (cortisol [Cor], norepinephrine [NE], glucose [Glu]), inflammatory cytokines (interleukin-1β, tumor necrosis factor-alpha, interleukin-10), pain intensity (visual analog scale [VAS] scores), recovery metrics, adverse events, and psychological outcomes were evaluated and compared. <b><i>Results:</i></b> The intervention group showed significantly shorter response recovery time, eye-opening time, spontaneous respiration recovery time, and extubation time than reference group (<i>p</i> < 0.05). Postoperative VAS scores decreased in both groups from 0.5 to 12 h, with the intervention group reporting consistently lower scores at all time points (<i>p</i> < 0.05). Hemodynamic parameters (heart rate, systolic blood pressure, diastolic blood pressure) and serum stress biomarkers (Cor, NE, Glu) were significantly lower in intervention group during key intraoperative periods (T1, T2, T3) (<i>p</i> < 0.05). Inflammatory cytokine levels rose intraoperatively in both groups, but were markedly lower in intervention group at T3, T4, and T5 (<i>p</i> < 0.05). The adverse reactions' incidence was also lower in intervention group (χ² = 4.523, <i>p</i> < 0.05). Both groups showed improved psychological status, comfort, and illness perception postintervention, with nursing satisfaction exceeding 90%. <b><i>Conclusions:</i></b> Remifentanil-propofol anesthesia, when combined with psychological intervention, provides superior control over the biological stress response, enhances analgesia, and promotes faster recovery compared with sevoflurane-propofol anesthesia in TC patients undergoing ultrasound-guided thyroidectomy. This approach is clinically beneficial and warrants broader application.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-Mediated Microbubble Disruption to Enhance Radiopharmaceutical Access to the Tumor Microenvironment in Immune-Resistant Lung Carcinoma.","authors":"Xue Yu, Shuai Zheng, Long Zhao, Kai Zhang","doi":"10.1177/10849785251371491","DOIUrl":"https://doi.org/10.1177/10849785251371491","url":null,"abstract":"<p><p><b><i>Background:</i></b> Immune-resistant lung carcinoma poses a major hurdle for effective cancer treatment, largely due to its dense tumor microenvironment (TME) and the challenges of drug penetration. To boost the effectiveness of radiopharmaceuticals in this intricate TME, focused ultrasound-mediated microbubble cavitation (FUS-MMC) needs to enhance their accessibility. Current delivery methods often fall short, suffering from limited vascular permeability and insufficient tumor uptake. This results in less effective treatments and increased off-target toxicity. <b><i>Methods:</i></b> To address this issue, this article proposes a targeted delivery framework that utilizes FUS-MMC. This innovative technique involves administering microbubbles systemically and directing ultrasound precisely to disrupt the tumor's blood vessels and extracellular matrix temporarily. By using the FUS-MMC approach, the permeability of the TME is improved, allowing radiopharmaceuticals like 177Lu-DOTATATE to penetrate deeper into the tumor tissues. This enhanced access leads to a more even distribution and greater accumulation of therapeutic agents right at the tumor site. <b><i>Results and Conclusion:</i></b> FUS-MMC significantly boosts the efficiency of radiopharmaceutical delivery, reduces systemic exposure, and improves tumor response rates in models of immune-resistant lung carcinoma. This noninvasive and repeatable strategy represents a promising step forward in precision oncology and targeted cancer therapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-Guided Percutaneous Radioactive ¹²⁵I Brachytherapy for Locally Advanced Pancreatic Cancer.","authors":"Peng Du, Liangliang Meng, Zenan Chen, Xiao Zhang","doi":"10.1177/10849785251380365","DOIUrl":"https://doi.org/10.1177/10849785251380365","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To explore the efficacy and safety of ¹²⁵I source implantation via a coaxial puncture in treating locally advanced pancreatic cancer (LAPC). <b><i>Methods:</i></b> A retrospective analysis was used to investigate the efficacy and safety of 40 patients with LAPC treated with radioactive ¹²⁵I particles under CT guidance in the hospital. A treatment planning system was used to develop the preoperative plan, and the radioactive ¹²⁵I particles were implanted using a coaxial puncture technique in the same plane to simulate a sector distribution system. CT scans were performed at postoperative months 2, 4, and 6 for follow-up treatment outcome assessment. Overall survival (OS) time and progression-free survival (PFS) were calculated, and factors affecting prognosis were assessed. <b><i>Results:</i></b> All patients completed the operation successfully. The overall response rate of treatment at 2, 4, and 6 months was 37.5%, 47.5%, and 50.0%. The median OS and PFS were 11.0 months (95% confidence interval [CI]: 9.14-12.86) and 9.0 months (95% CI: 7.45-10.55), respectively. The 6- and 12-month PFS rates were 85.0% (95% CI: 69.6%-93.0%) and 35.0% (95% CI: 20.8%-49.5%), respectively. The 12-month OS rates were 47.5% (95% CI: 20.2%-49.8%). The intraoperative complications related to the operation were local abdominal hemorrhage in 2 cases, subcutaneous soft tissue hematoma in 2 cases, and wrong puncture of the pancreatic duct in 1 case. The main side-effects were fever in 10 cases and decreased appetite in 3 cases in the recent postoperative period. Eighteen grade 0 cases and 3 cases of grade I acute radiation enteritis occurred. No acute radiation damage above grade II and late radiation damage was observed. <b><i>Conclusions:</i></b> Coaxial puncture ¹²⁵I source implantation is a promising percutaneous minimally invasive technology that is safe and effective in treating LAPC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}